Condition: Neoplasm · Cancer, Malignant Tumors · Sponsor: Compugen Ltd
The overall goal of this first-in-human (FIH) clinical trial is to learn about the safety and dosing of COM503 when given alone or in combination with zimberelimab in participants with advanced solid tumors. The primary objectives of this study are: * To assess the safety and tolerability of COM503 as monotherapy and COM503 in combination with zimberelimab in participants with advanced solid tumors. * To identify the maximum tolerated dose (MTD) / maximum administered dose (MAD) and/or the recommended phase 2 dose (RP2D) of COM503 as monotherapy and in combination with zimberelimab in participants with advanced solid tumors.
This description comes directly from the study's public registry record.
Michelle Chief Medical Officer, MD · +14153734034 · michellebm@cgen.com
Always discuss trial participation with your own doctor first.
| Yale- New Haven Hospital- Yale Cancer Center | New Haven, Connecticut, United States | Recruiting |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
| START Midwest | Grand Rapids, Michigan, United States | Recruiting |
| The West Clinic, PLCC dba West Cancer Center | Germantown, Tennessee, United States | Recruiting |
| NEXT Oncology San Antonio | San Antonio, Texas, United States | Recruiting |
| START | San Antonio, Texas, United States | Recruiting |
| NEXT Oncology Virginia | Fairfax, Virginia, United States | Recruiting |
| Rambam Health Care Campus | Haifa, Israel, Israel | Recruiting |
| Hadassah University Medical Center- Ein Kerem | Jerusalem, Israel, Israel | Recruiting |
| Rabin Medical Center | Petah Tikva, Israel, Israel | Recruiting |
| The Chaim Sheba Medical Center | Ramat Gan, Israel, Israel | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06759649